AMS AG UNSPON.ADR/1/2

AMS shareholders have approved the planned cash takeover by H.B. Fuller, a milestone since the announcement on 25 June 2026. H.B. Fuller expects the transaction to close by the end of the year, subject to further regulatory approvals and contractual conditions. The company says the combination of AMS medical technologies and H.B. Fuller’s global reach should enable growth, higher margins and a stronger healthcare platform. » Más en de.investing.com

TA Associates has confirmed it does not intend to make an offer for the entire issued and to‑be‑issued share capital of AMS. The decision follows earlier reviews of a possible offer and was disclosed under Rule 2.8 of the City Code on Takeovers and Mergers. TA Associates reserves the right, in certain circumstances, to lift the Takeover Panel’s restrictions. » Más en de.investing.com

AMS reports preliminary 2025 revenue growth of 29%, an adjusted EBITDA increase of 24% and adjusted diluted earnings per share up 12%. Adjusted EPS was £0.12 (unadjusted £0.05), and adjusted pre-tax profit was £33.90m versus £17.80m total. The board proposes a 10% increase in the annual dividend. For 2026 AMS expects revenue of £245.3m and adjusted EBITDA of £55.2m, supported by strong surgical businesses, a recovery in the woundcare segment and the full contribution of the acquisitions Peters Surgical and Syntacoll; several product approvals have been announced. » Más en de.investing.com